Aescap logo

It's all about People

Aescap 2.0

Aescap 2.0 is an open-end fund that invests in publicly listed biotech / life sciences companies. It invests in highly innovative companies that develop and market new medicines and to a lesser extent diagnostics and/or medical devices.

The life sciences market is a large and fast-growing market where breakthrough innovations can be harnessed in a global and profitable manner. The substantial growth of the life sciences market is driven by:

  1. A longer life expectancy (especially in the emerging markets) as well as an ageing population, which both are driving demand for improved and cost-effective medicine, diagnostics and medical devices;
  2. A high unmet medical need for diseases such as Alzheimer, Arthrosis, Diabetes, MS, Obesity, Oncology, Parkinson and many other diseases;
  3. Approximately 6,000 rare diseases with no treatment available at all today.

Aescap 2.0 has a focused portfolio, investing in approximately 18 companies. Within this focus it will ensure that the portfolio is diversified over different diseases, development phases and geographies. The Fund’s objective is to make an average minimum annual net return (after deduction of costs) of 20%+ over the mid-term (4-5 years).

The name Aescap is derived from Aesculapius, the Roman god of medicine, and Capital. The first fund under the Aescap name was Aescap 1, a venture capital fund investing in the life science industry that was launched by Dinko Valerio, Michiel de Haan and Patrick Krol mid-2006. Subsequently, in March 2016 Aescap 2.0 was launched by Portfolio Manager Patrick Krol.

 

Patrick Krol

The Portfolio Manager of Aescap 2.0 is Patrick Krol who has more than 30 years of experience in the healthcare industry. He developed an investment strategy based on his own experiences over many years as an investor in private as well as public medical companies.

 

Fund Management

Aescap 2.0 will be managed by Privium Fund Management B.V. (Privium) as Alternative Investment Fund Manager of the Fund. Privium is an asset manager with offices in Amsterdam, London and Hong Kong which focuses on alternative investments. The Fund Manager is responsible for the entire management of the Fund in accordance with the provisions of the Fund Documents and applicable laws. The Fund Manager is also responsible for maintaining records and furnishing or causing to be furnished all required records or other information of the Fund to the extent such records, reports and other information are not maintained or furnished by the Administrator, the Legal Owner, the Depositary or other service providers. Privium Fund Management B.V. is authorized and regulated by the Dutch Authority for the Financial Markets (www.afm.nl) as an Alternative Investment Fund Manager (AIFM) as referred to in article 2:65 (a). Both Privium and the Fund are registered in the register of the AFM. Privium as a group is managing over USD 2.3 billion. For additional information on the fund manager please visit Privium´s website at: www.privumfund.com.